RINZIVILLO, MARIA
 Distribuzione geografica
Continente #
NA - Nord America 1.533
EU - Europa 586
AS - Asia 170
AF - Africa 17
SA - Sud America 9
OC - Oceania 3
Totale 2.318
Nazione #
US - Stati Uniti d'America 1.504
IT - Italia 291
IE - Irlanda 90
SE - Svezia 84
SG - Singapore 77
IN - India 59
FI - Finlandia 41
CN - Cina 26
CA - Canada 25
GB - Regno Unito 16
UA - Ucraina 13
DE - Germania 12
BG - Bulgaria 10
TG - Togo 10
AR - Argentina 6
AT - Austria 5
BE - Belgio 5
RO - Romania 5
UG - Uganda 5
MX - Messico 4
SI - Slovenia 4
BR - Brasile 3
CH - Svizzera 3
FR - Francia 3
PH - Filippine 3
PK - Pakistan 3
AU - Australia 2
NG - Nigeria 2
ES - Italia 1
IQ - Iraq 1
LI - Liechtenstein 1
MY - Malesia 1
NL - Olanda 1
NZ - Nuova Zelanda 1
PL - Polonia 1
Totale 2.318
Città #
Fairfield 323
Chandler 139
Ashburn 107
Rome 97
Dublin 88
Woodbridge 88
Seattle 73
Cambridge 72
Houston 72
Wilmington 50
Princeton 49
Lawrence 45
Millbury 42
New York 40
San Paolo di Civitate 39
Singapore 31
San Diego 30
Ann Arbor 25
Milan 18
Ottawa 18
Helsinki 16
Lappeenranta 16
Beijing 12
Boston 12
Plano 11
Lomé 10
Sofia 10
Shanghai 9
Andover 8
Des Moines 7
Fara in Sabina 7
London 7
Norwalk 7
Boardman 6
Dearborn 6
Federal 6
Bologna 5
Brussels 5
Calvanico 5
Grottammare 5
Kampala 5
Toronto 5
Falls Church 4
Ljubljana 4
Phoenix 4
San Mateo 4
Terni 4
Bühl 3
Cebu City 3
Islamabad 3
Naples 3
Palmetto 3
Pontedera 3
Redmond 3
Segrate 3
Tenhult 3
Vienna 3
Vignola 3
Atlanta 2
Birmingham 2
Bremen 2
Casanova Lonati 2
Catania 2
Civita Castellana 2
El Paso 2
Fremont 2
Hyderabad 2
Lagos 2
Lake City 2
Lamezia Terme 2
Macerata 2
Mannheim 2
Marino 2
Menlo Park 2
Mexico City 2
Nanjing 2
Nocera Inferiore 2
Ozzano dell'Emilia 2
Palermo 2
Paris 2
Prescot 2
Québec 2
Sacramento 2
Trescore Balneario 2
Veroli 2
Verona 2
Vevey 2
Vezzano sul Crostolo 2
Zola Predosa 2
Americana 1
Bari 1
Bern 1
Chiswick 1
Civitavecchia 1
Como 1
Deruta 1
Erie 1
Grafing 1
Guagnano 1
Guangzhou 1
Totale 1.752
Nome #
A case of pancreatic small cell neuroendocrine carcinoma associated with SIADH 104
CT texture analysis of liver metastases in PNETs versus NPNETs. correlation with histopathological findings 93
Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms 86
[18F]FDG-PET/CT and long-term responses to everolimus in advanced neuroendocrine neoplasia 84
Role of combined [68Ga]Ga-DOTA-SST analogues and [18F]FDG PET/CT in the management of GEP-NENs. a systematic review 81
[18F]FDG-PET/CT and long-term response to everolimus in advanced neuroendocrine neoplasia 77
Real-world study of everolimus in advanced progressive neuroendocrine tumors. 76
Occurrence of exocrine pancreatic insufficiency in patients with advanced neuroendocrine tumors treated with somatostatin analogs 69
Role of [18F]FDG PET/CT in the management of G1 gastro-entero-pancreatic neuroendocrine tumors 68
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues 67
Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases. 65
Digestive neuroendocrine neoplasms. A 2016 overview 64
Heterogeneity of duodenal neuroendocrine tumors: an Italian multi-center experience 62
Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: a real-world study 62
Multidisciplinary management of neuroendocrine neoplasia: a real-world experience from a referral center 62
Usefulness of 68-Gallium PET in Type I Gastric Neuroendocrine Neoplasia. A Case Series 57
Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs. A Multicenter Study 54
Comparison of Endoscopic Techniques in the Management of Type I Gastric Neuroendocrine Neoplasia. A Systematic Review 50
Advanced digestive neuroendocrine tumors. metastatic pattern is an independent factor affecting clinical outcome 44
Management of type-I gastric neuroendocrine neoplasms. A 10-years prospective single centre study 44
Role of Resection of the Primary Pancreatic Neuroendocrine Tumour Only in Patients with Unresectable Metastatic Liver Disease: A Systematic Review. 43
Risk factors for sporadic pancreatic endocrine tumors: a case-control study of prospectively evaluated patients. 43
Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors 42
Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia. a multicentre retrospective study 41
Octreotide long-acting release (LAR) in combination with other therapies for treatment of neuroendocrine neoplasia. A systematic review 41
Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≤2 cm. Study Protocol for a Prospective Observational Study 41
Clinical Usefulness of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Diagnostic Algorithm of Advanced Entero-Pancreatic Neuroendocrine Neoplasms 40
Exocrine pancreatic insufficiency and somatostatin analogs in patients with neuroendocrine neoplasia 38
CT-based radiomics for prediction of therapeutic response to Everolimus in metastatic neuroendocrine tumors 37
Competitive testing of the WHO 2010 versus the WHO 2017 grading of pancreatic neuroendocrine neoplasms. Data from a large international cohort study 37
Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix. A Multicentric Retrospective Study 36
Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms. The NOVARA Score, a Multicentre Retrospective Study 36
Prognostic significance of laterality in lung neuroendocrine tumors 35
Efficacy of lutetium-peptide receptor radionuclide therapy in inducing prolonged tumour regression in small-bowel veuroendocrine tumours. A case of favourable response to retreatment after Initial objective response 34
The ENETS TNM staging and grading system accurately predict prognosis in patients with rectal NENs 34
Linee guida NEOPLASIE NEUROENDOCRINE 33
Bone Metastases in Neuroendocrine Tumors. Molecular Pathogenesis and Implications in Clinical Practice 31
Everolimus in pancreatic neuroendocrine carcinomas G3 30
Effect of Neuroendocrine Neoplasm Treatment on Human Reproductive Health and Sexual Function 29
Tumor heterogenity in gastro-entero-pancreatic neuroendocrine neoplasia 29
What gastroenterologists should know about carcinoid syndrome 28
Gastro-entero-pancreatic neuroendocrine neoplasia. The rules for non-operative management 28
Second primary neoplasms in patients with lung and gastroenteropancreatic neuroendocrine neoplasms: data from a retrospective multi-centric study 27
Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet) 27
Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database 26
Risk of preoperative understaging of duodenal neuroendocrine neoplasms. a plea for caution in the treatment strategy 26
Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: a comparison between pancreatic and gastrointestinal localizations 25
Sporadic non-functioning pancreatic neuroendocrine tumours. multicentre analysis 25
Management of functional pancreatic neuroendocrine neoplasms 23
Reply to Dr. Hall and coworkers 23
The role of combined Ga-DOTANOC and 18FDG PET/CT in the management of patients with pancreatic neuroendocrine tumors 21
Stage IV gastro-entero-pancreatic neuroendocrine neoplasms. A risk score to predict clinical outcome 19
Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors 19
Utility of histopathological revision in the management of gastro-entero-pancreatic neuroendocrine neoplasia 17
Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastro entero pancreatic neuroendocrine tumors. alternatives to RECIST 15
Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1-2 cm in size. a retrospective, Europe-wide, pooled cohort study 14
The Antiproliferative Activity of High-Dose Somatostatin Analogs in Gastro-Entero-Pancreatic Neuroendocrine Tumors. A Systematic Review and Meta-Analysis 14
Targeting neuroendocrine tumors with octreotide and lanreotide. Key points for clinical practice from NET specialists 14
Novel molecular targets for the treatment of gastroenteropancreatic endocrine tumors. Answers and Unsolved Problems 14
Diagnostic and therapeutic management of primary orbital neuroendocrine tumors (NETs): systematic literature review and clinical case presentation 13
Survival after active surveillance versus upfront surgery for incidental small pancreatic neuroendocrine tumours 12
Controversies in the treatment of digestive neuroendocrine tumors 11
Necrolytic migratory erythema impact on prognosis and diagnosis of glucagonoma: a case report 11
MYC Upregulation Confers Resistance to Everolimus and Establishes Vulnerability to Cyclin-Dependent Kinase Inhibitors in Pancreatic Neuroendocrine Neoplasm Cells 10
Therapy for Locoregional Disease. Stomach/Duodenum, Colon/Rectum 10
Type 3 gastric neuroendocrine neoplasms: the rising promise of conservative endoscopic management 9
Treatment of Intestinal NETs (Including Appendix) 9
Thyroid transcription factor-1 expression in lung neuroendocrine tumours: a gender-related biomarker? 8
Risk and protective factors for small intestine neuroendocrine tumors: a prospective case-control study 7
Clinical outcome of patients with gastric, duodenal, or rectal neuroendocrine tumors after incomplete endoscopic resection 6
Metastatic Type 1 low-grade gastric neuroendocrine tumor treated with peptide receptor radionuclide therapy in a young adult: a case report 6
Sequencing treatments in patients with advanced well-differentiated pancreatic neuroendocrine tumor (pNET): results from a large multicenter italian cohort 6
Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm. interim analysis of prospective ASPEN trial 5
New Prognostic Frontiers for Lung Neuroendocrine Tumors 3
Totale 2.630
Categoria #
all - tutte 11.093
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.093


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020296 23 16 5 11 28 25 44 40 43 27 15 19
2020/2021175 20 14 20 12 5 4 0 9 23 27 22 19
2021/2022857 2 14 19 14 52 19 17 49 173 100 312 86
2022/2023690 98 141 44 46 70 43 11 38 125 17 38 19
2023/2024483 30 50 17 43 32 65 39 34 13 49 68 43
2024/202515 15 0 0 0 0 0 0 0 0 0 0 0
Totale 2.630